We thank the following specialists and researchers into the diagnosis and management of prostate cancer for their participation as members of our Scientific Advisory Board. They receive no remuneration for this kindness.
Judd W. Moul, MD, FACS (Chairman) — Dr. Moul is professor and chief, Division of Urologic Surgery, and director of the Duke Prostate Center, Duke University Health System, Durham, North Carolina. He is an internationally respected member of the urologic oncology community and was the founding director of the Center for Prostate Disease Research at the Uniformed Services University of the Health Sciences in Rockville, MD and at Walter Reed Army Medical Center in Washington, DC. For additional information about Dr. Moul, please click here.
Timothy B. Boone, MD, PhD — Dr. Boone is Chairman of the Urology Department and medical director of the Urodynamic Laboratory at the The Methodist Hospital System, Houston, Texas. He specializes in issues related to urinary incontinence, specifically including incontinence consequent to radical prostatectomy. For additional information about Dr. Boone, please click here.
David G. Bostwick, MD, MBA — Dr. Bostwick is the chief medical officer of Bostwick Laboratories, Inc., one of the world’s most respected commercial pathology laboratories, exclusively focused on diagnosis of cancer of urologic organs (prostate, urinary bladder, kidney, and testis) and with a special interest in prostate cancer. He was formerly a professor of pathology and urology at the Mayo Clinic, which he left to found Bostwick Laboratories. He is also a past president of the International Society of Urological Pathology. For additional information about Dr. Bostwick, please click here.
Michael Burke, MD — Dr. Burke is clinical director of psychiatric oncology at the Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia. For 15 years he has provided care for and education about the psychological and social issues that often accompany prostate cancer patients and families. His research has also been focused on quality of life issues in men with prostate cancer. He was a founding member of the VA Interdisciplinary Prostate Cancer Clinic in Miami, Florida (one of the first such clinics in the world). For additional information about Dr. Burke, please click here.
Arthur L. Burnett, II, MD — Dr. Burnett is professor, Department of Urology, at Johns Hopkins University School of Medicine, where he is also Director of the Basic Science Laboratory in Neuro-urology. He is recognized as a world authority in the science and medicine of male erectile dysfunction. Currently, Dr. Burnett holds professional appointments at the Johns Hopkins Hospital, including Director of the Male Consultation Clinic and clinician-scientist at the James Buchanan Brady Urological Institute. For more information about Dr. Burnett, please click here.
Barrie R. Cassileth, MS, PhD — Dr. Cassileth holds the Laurance S. Rockefeller Chair in Integrative Medicine and is chief of the Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York. She has worked in alternative and complementary (integrative) medicine and psychosocial aspects of cancer care for over 25 years. She joined MSKCC in 1999 to create the Integrative Medicine Service, a program that offers inpatient therapies at Memorial Hospital and outpatient services at the Bendheim Integrative Medicine Center. For additional information about Dr. Cassileth, please click here.
Mark Emberton, MD, FRCS — Mr. Emberton is a clinical researcher with particular interest in minimally invasive forms of treatment for localized prostate cancer. He is Director of the Division of Surgery and Interventional Science at University College London (UCL), UCL Partners’ Pathway Director for urological oncology for London Cancer, and the Honorary Clinical Director of the Clinical Effectiveness Unit at the Royal College of Surgeons of England. He has special interests in methodological aspects of clinical research, including alternatives to the randomized control trial in surgery. For additional information about Mr. Emberton, please click here.
Philip Kantoff, MD — Dr. Kantoff is one of the world’s pre-eminent authorities on advanced prostate cancer. He is a professor of medicine at Harvard Medical School and director of the Lank Center for Genitourinary Oncology in the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. He is also the leader of the Dana-Farber/Harvard Cancer Center Prostate Cancer Program; director of the prostate cancer Specialized Program of Research Excellence (SPORE); and chief clinical research officer and chief of the Division of Solid Tumor Oncology at Dana-Farber. For additional information about Dr. Kantoff, please click here.
Mark S. Litwin, MD, MPH — Dr. Litwin is Professor and Chairman of the Department of Urology, UCLA Healthcare and Professor of Public Health, UCLA School of Public Health, University of California Los Angeles, Los Angeles, California. His practice is limited to urologic oncology and emphasises health-related quality of life in men with prostate cancer, medical outcomes in urologic oncology, and the epidemiologic burden of urologic diseases in America. One of his long-time research interests has been the quality of men’s lives after treatment for early and late stage prostate cancer. He created and directs IMPACT, a public assistance program for low-income, uninsured California men with prostate cancer. For additional information about Dr. Litwin, please click here.
Lydia T. Madsen, RN, MSN, APN — Ms. Madsen is an advanced practice nurse in the Department of Genitourinary Medical Oncology at the University of Texas M. D. Anderson Cancer Center and a Clinical Instructor in Nursing at the University of Texas School of Nursing in Houston, Texas. She coordinates all daily activities of the Multidisciplinary Prostate Cancer Clinic at M. D. Anderson, including patient assessments, referrals for diagnostic and ancillary services, screening and education of appropriate protocols, follow-up in the decision making process for the patient, and final treatment disposition.
Heather Payne, MB BS, MRCP, FRCR — Dr. Payne is a Consultant in Clinical Oncology at University College London Hospitals and at The Institute of Urology, London, England. Working within a multidisciplinary team, she is the lead in treatments for prostate cancer with radiotherapy, hormone therapy, and novel therapies, and she has pioneered a program of high dose rate brachytherapy. Her research interests, include hormone therapy, radiotherapy, chemotherapy, and quality of life and decision making for men with prostate cancer. For additional information about Dr. Payne, please click here.
Howard M. Sandler, MD — Dr. Sandler is Chairman of Radiation Oncology and Ronald H. Bloom Family Chair in Cancer Therapeutics at Cedars-Sinai Medical Center in Los Angeles, California. He has particular interests in the quality of life of prostate cancer patients following radiation and surgery as well as in dose escalation and novel techniques for prostate irradiation. He is actively involved in prostate cancer clinical trial implementation through the Radiation Therapy Oncology Group (RTOG).
J. Brantley Thrasher, MD, FACS — Dr. Thrasher is Professor and William L. Valk Chair of Urology and Co-Director of the Operative Services at the University of Kansas Medical Center in Kansas City, Kansas. He is involved in basic and clinical research into the development of new diagnostic techniques and treatments for prostate, bladder and kidney cancer. His many editorial appointments include membership of the Editorial Advisory Board of American Family Physician (which has one of the largest circulations of any medical journal). For more information about Dr. Thrasher, please click here.
Andrew Vickers, PhD — Dr. Vickers is Attending Research Methodologist in the Department of Epidemiology and Biostatistics at Memorial Sloan-Kettering Cancer Center in New York City, New York. His research is focused on novel methods for assessing the clinical value of predictive tools, and he has a special interest in the detection and initial treatment of prostate cancer. He is also researching methods for integrating randomized trials into routine surgical practice in ways that will allow comparisons of different types of surgery. For additional information about Dr. Vickers, please click here.
THE "NEW" PROSTATE CANCER INFOLINK 